Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain

Molecular Biology of the Cell

Volumn 14, Issue 4, 2003, Pages 1448-1459

  Saharinen, Pipsa ^a,b   Vihinen, Mauno ^c,d   Silvennoinen, Olli ^a,b,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

JAK2 TYROSINE KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; AUTOREGULATION; CARBOXY TERMINAL SEQUENCE; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR MODEL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FOLDING; REGULATORY MECHANISM;

AMINO ACID SEQUENCE; CELL LINE; ESCHERICHIA COLI; HUMANS; JANUS KINASE 2; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 0038371050     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E02-06-0342     Document Type: Article

References (50)

1. Abola, E.E., Sussman, J.L., Prilusky, J., and Manning, N.O. (1997). Protein Data Bank archives of three-dimensional macromolecular structures. Methods Enzymol 277, 556-571.
2. Al-Lazikani, B., Sheinerman, F.B., and Honig, B. (2001). Combining multiple structure and sequence alignments to improve sequence detection and alignment: application to the SH2 domains of Janus kinases. Proc. Natl. Acad. Sci. USA 98, 14796-14801.
3. Andreotti, A.H., Bunnell, S.C., Feng, S., Berg, L.J., and Schreiber, S.L. (1997). Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature 385, 93-97.
4. Candotti, F., et al. (1997). Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 90, 3996-4003.
5. Chen, M., Cheng, A., Candotti, F., Zhou, Y.J., Hymel, A., Fasth, A., Notarangelo, L.D., and O'Shea, J.J. (2000). Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20, 947-956.
6. Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
7. Dodelet, V.C., and Pasquale, E.B. (2000). Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19, 5614-5619.
8. Feng, J., Witthuhn, B.A., Matsuda, T., Kohlhuber, F., Kerr, I.M., and Ihle, J.N. (1997). Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17, 2497-2501.
9. Gauzzi, M.C., Velazquez, L., McKendry, R., Mogensen, K.E., Fellous, M., and Pellegrini, S. (1996). Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271, 20494-20500.
10. Gouilleux, F., Wakao, H., Mundt, M., and Groner, B. (1994). Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 13, 4361-4369.
11. Gupta, S., Yan, H., Wong, L.H., Ralph, S., Krolewski, J., and Schindler, C. (1996). The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-α signals. EMBO J. 15, 1075-1084.
12. Hansson, H., Okoh, M.P., Smith, C.I., Vihinen, M., and Hard, T. (2001). Intermolecular interactions between the SH3 domain and the proline-rich TH region of Bruton's tyrosine kinase. FEBS Lett. 489, 67-70.
13. Higgins, D.G., Thompson, J.D., and Gibson, T.J. (1996). Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 266, 383-402.
14. Hubbard, S.R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581.
15. Hubbard, S.R., Mohammadi, M., and Schlessinger, J. (1998). Auto-regulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273, 11987-11990.
16. Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K., and Silvennoinen, O. (1995). Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13, 369-398.
17. Irie-Sasaki, J., et al. (2001). CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature 409, 349-354.
18. Klingmuller, U., Lorenz, U., Cantley, L.C., Neel, B.G., and Lodish, H.F. (1995). Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80, 729-738.
19. Kohlhuber, F., et al. (1997). A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol. Cell. Biol. 17, 695-706.
20. Lacronique, V., Boureux, A., Valle, V.D., Poirel, H., Quang, C.T., Mauchauffe, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., and Bernard, O.A. (1997). A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312.
21. Liu, K.D., Gaffen, S.L., Goldsmith, M.A., and Greene, W.C. (1997). Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. 7, 817-826.
22. Luo, H., Rose, P., Barber, D., Hanratty, W.P., Lee, S., Roberts, T.M., D'Andrea, A.D., and Dearolf, C.R. (1997). Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 17, 1562-1571.
23. Mizushima, S., and Nagata, S. (1990). pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18, 5322.
24. Moarefi, I., LaFevre-Bernt, M., Sicheri, F., Huse, M., Lee, C.H., Kuriyan, J., and Miller, W.T. (1997). Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385, 650-653.
25. Myers, M.P., Andersen, J.N., Cheng, A., Tremblay, M.L., Horvath, C.M., Parisien, J.P., Salmeen, A., Barford, D., and Tonks, N.K. (2001). TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276, 47771-47774.
26. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998). Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409.
27. O'Brien, K.B., O'Shea, J.J., and Carter-Su, C. (2001). SH2-B family members differentially regulate JAK family tyrosine kinases. J. Biol. Chem. 277, 8673-8681.
28. Okoh, M.P., and Vihinen, M. (2002). Interaction between Btk TH and SH3 domain. Biopolymers 63, 325-334.
29. Parganas, E., et al. (1998). Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395.
30. Pine, R., Canova, A., and Schindler, C. (1994). Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J. 13, 158-167.
31. Pluk, H., Dorey, K., and Superti-Furga, G. (2002). Autoinhibition of c-Abl. Cell 108, 247-259.
32. Rui, L., and Carter-Su, C. (1999). Identification of SH2-bbeta as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc. Natl. Acad. Sci. USA 96, 7172-7177.
33. Saharinen, P., Ekman, N., Sarvas, K., Parker, P., Alitalo, K., and Silvennoinen, O. (1997). The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cδ. Blood 90, 4341-4353.
34. Saharinen, P., and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963.
35. Saharinen, P., Takaluoma, K., and Silvennoinen, O. (2000). Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395.
36. Schultz, J., Milpetz, F., Bork, P., and Ponting, C.P. (1998). SMART, a simple modular architecture research tool: identification of signaling domains. Proc. Natl. Acad. Sci. USA 95, 5857-5864.
37. Sicheri, F., Moarefi, I., and Kuriyan, J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609.
38. Thompson, J.D., Higgins, D.G., and Gibson, T.J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673-4680.
39. Ungureanu, D., Saharinen, P., Junttila, I., Hilton, D.J., and Silvennoinen, O. (2002). Regulation of Jak2 through the ubiquitin-protea-some pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell. Biol. 22, 3316-3326.
40. Watling, D., et al. (1993). Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-γ signal transduction pathway. Nature 366, 166-170.
41. Velazquez, L., Mogensen, K.E., Barbieri, G., Fellous, M., Uze, G., and Pellegrini, S. (1995). Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-α/β and for signal transduction. J. Biol. Chem. 270, 3327-3334.
42. Vihinen, M., Euranto, A., Luostarinen, P., and Nevalainen, O. (1992). MULTICOMP: a program package for multiple sequence comparison. Comput. Appl. Biosci. 8, 35-38.
43. Vihinen, M., Villa, A., Mella, P., Schumacher, R.F., Savoldi, G., O'Shea, J.J., Candotti, F., and Notarangelo, L.D. (2000). Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency. Clin. Immunol. 96, 108-118.
44. Wybenga-Groot, L.E., Baskin, B., Ong, S.H., Tong, J., Pawson, T., and Sicheri, F. (2001). Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106, 745-757.
45. Xu, W., Doshi, A., Lei, M., Eck, M.J., and Harrison, S.C. (1999). Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, 629-638.
46. Xu, W., Harrison, S.C., and Eck, M.J. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602.
47. Yasukawa, H., et al. (1999). The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320.
48. Yeh, T.C., Dondi, E., Uze, G., and Pellegrini, S. (2000). A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling. Proc. Natl. Acad. Sci. USA 97, 8991-8996.
49. Zhou, Y.J., Hanson, E.P., Chen, Y.Q., Magnuson, K., Chen, M., Swann, P.G., Wange, R.L., Changelian, P.S., and O'Shea, J.J. (1997). Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94, 13850-13855.
50. Ziemiecki, A., Harpur, A., and Wilks, A. (1994). JAK protein tyrosine kinases: their role in cytokine signaling. Trends Cell Biol. 4, 207-212.